GSAP
Summary: Accumulation of neurotoxic amyloid-beta is a major hallmark of Alzheimer disease (AD; MIM 104300). Formation of amyloid-beta is catalyzed by gamma-secretase (see PSEN1; MIM 104311), a protease with numerous substrates. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and its substrate, the amyloid-beta precursor protein (APP; MIM 104760) C-terminal fragment (APP-CTF) (He et al., 2010 [PubMed 20811458]).[supplied by OMIM, Nov 2010].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
gamma-secretase activating protein | MIM:613552 | Ensembl:ENSG00000186088 | HGNC:HGNC:28042 | PA164724500 | 7q11.23 |
GO terms in GSAP
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
BP | IDA | GO:0030162 | regulation of proteolysis |
BP | IDA | GO:1902004 | positive regulation of amyloid-beta formation |
CC | IDA | GO:0005802 | trans-Golgi network |
MF | IDA | GO:0001540 | amyloid-beta binding |
MF | IPI | GO:0005515 | protein binding |
Gene expression in normal tissue: GSAP
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in GSAP
Database | Pathway ID | Pathway Des. |
---|
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in GSAP